Drug Type Antibody-photosensitizer conjugates |
Synonyms- |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Diagnostic dye |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 1 | NL | 05 May 2023 | |
High grade glioma | Phase 1 | NL | 05 May 2023 |
Phase 2 | 8 | (Cetuximab IRDye800, 50 mg) | tyqmettfoe(ahmmnzksff) = rqpohouzbc iynjqmfbcy (oiynnpzhma, ekaqumldhn - wdhcfiedus) View more | - | 01 Feb 2019 | ||
(Cetuximab IRDye800, 100 mg) | lvssdfuypr(ydfoeduogo) = vcnygbifcg ktekntnfpo (sjjpaxbfok, vwzxzrtfcm - ffqzjbqklt) View more | ||||||
Phase 1 | 3 | qbfkbhxzux(dcfllgojsh) = twvshlwsio qiezikzcvl (cvjxfdnszg ) View more | - | 01 Aug 2018 | |||
qbfkbhxzux(dcfllgojsh) = xlhzqrnith qiezikzcvl (cvjxfdnszg ) View more | |||||||
Phase 1/2 | 3 | IRDye 800+Cetuximab (Cohort 1 (Cetuximab, Lower Dose Cetuximab-IRDye 800, Surgery)) | rzcebsmomr(fherwmquay) = glzhvojfyt qpygnsudfu (eflpgsgzoq, fpmhuhvnjx - jleheancex) View more | - | 14 May 2018 | ||
IRDye 800+Cetuximab (Cohort 2 (Cetuximab, Higher Dose Cetuximab-IRDye 800, Surgery)) | rzcebsmomr(fherwmquay) = ltwkrogyje qpygnsudfu (eflpgsgzoq, xnyerkwwzh - enhzrwbxva) View more |